Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study - Ryan, Charles J; Smith, Matthew R; Fizazi, Karim; Saad, Fred; Mulders, Peter F A; Sternberg, Cora N; Miller, Kurt; Logothetis, Christopher J; Shore, Neal D; Small, Eric J; Carles, Joan; Flaig, Thomas W; et al. (The lancet oncology, 2015)
Keywords: Aged; Androstenes - therapeutic use; Antineoplastic Agents, Hormonal - therapeutic use; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms - drug therapy; Bone Neoplasms - mortality; Bone Neoplasms - secondary; Cancer and Oncology; Cancer och onkologi; Chemotherapy; Clinical Medicine; Disease Progression; Double-Blind Method; Drug therapy; Follow-Up Studies; Hematology, Oncology and Palliative Medicine; Humans; Klinisk medicin; Male; Medical and Health Sciences; Medical research; Medicin och hälsovetenskap; Neoplasm Staging; Prednisone - therapeutic use; Prognosis; Prostate cancer; Prostatic Neoplasms, Castration-Resistant - drug therapy; Prostatic Neoplasms, Castration-Resistant - mortality; Prostatic Neoplasms, Castration-Resistant - pathology; Survival Rate